Journal
INTERNATIONAL JOURNAL OF PHARMACEUTICS
Volume 496, Issue 2, Pages 414-420Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijpharm.2015.10.039
Keywords
Three dimensional printing; Modified release; Fused filament fabrication; Budesonide; Inflammatory bowel disease; Colonic delivery
Categories
Ask authors/readers for more resources
The aim of this work was to explore the feasibility of using fused deposition modelling (FDM) 3D printing (3DP) technology with hot melt extrusion (HME) and fluid bed coating to fabricate modified-release budesonide dosage forms. Budesonide was sucessfully loaded into polyvinyl alcohol filaments using HME. The filaments were engineered into capsule-shaped tablets (caplets) containing 9 mg budesonide using a FDM 3D printer; the caplets were then overcoated with a layer of enteric polymer. The final printed formulation was tested in a dynamic dissolution bicarbonate buffer system, and two commercial budesonide products, Cortiment (R) (Uceris (R)) and Entocort (R), were also investigated for comparison. Budesonide release from the Entocort (R) formulation was rapid in conditions of the upper small intestine while release from the Cortiment (R) product was more delayed and very slow. In contrast, the new 3D printed caplet formulation started to release in the mid-small intestine but release then continued in a sustained manner throughout the distal intestine and colon. This work has demonstrated the potential of combining FDM 3DP with established pharmaceutical processes, including HME and film coating, to fabricate modified release oral dosage forms. (C) 2015 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available